Parker Institute for Cancer Immunotherapy investigators will present the latest findings in immuno-oncology research at the Fourth International Cancer lmmunotherapy Conference (#CICON18) in New York City, September 30 through October 3.
This global conference delves into pre-clinical and clinical immunotherapy research from top scientists in Europe and the United States who are engineering the best new solutions to cancer. Topics include genetically engineered T-cells, personalized cancer vaccines and T-cell regulation tactics. They also will discuss the role of the microbiome and metabolism in cancer.
The event is co-organized by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI) and the American Association for Cancer Research (AACR). Parker Institute scientific steering committee member Elizabeth Jaffee, M.D., of Johns Hopkins University and Parker Institute investigator Nina Bhardwaj, M.D., Ph.D., of the Icahn School of Medicine at Mount Sinai are two of the conference’s four co-chairs this year.
Parker Institute scientists also are among the event’s awardees, panel co-chairs and speakers. Below are select sessions featuring Parker Institute researchers.
Padmanee Sharma Receives William B. Coley Award for Tumor Immunology
Sept. 30, 2018, 2:15-2:45 p.m. EDT
Padmanee Sharma, M.D., Ph.D., Parker Institute center co-director at The University of Texas MD Anderson Cancer Center, will speak about response and resistance to immune checkpoint therapy at the event’s premier award lecture.
Genetically Engineered T Cells
Oct. 1, 2018, 8:45-12:45 p.m. EDT
Crystal Mackall, M.D., Parker Institute center director at Stanford Medicine, chairs this symposium with Jedd Wolchok, M.D., Ph.D., Parker Institute Center Director at Memorial Sloan Kettering Cancer Center. Speakers include Steven Rosenberg, M.D., Ph.D., of the National Cancer Institute, Parker Institute scientist Philip Greenberg, M.D., of Fred Hutchinson Cancer Research Center and Christopher Klebanoff, M.D., a Parker Institute investigator at Memorial Sloan Kettering Cancer Center.
Cancer Vaccines: Novel Vaccine Platforms and Combinations
Oct. 2, 2018, 8:15 a.m.-12:45 p.m. EDT
Nina Bhardwaj, M.D., Ph.D., a Parker Institute investigator at the Icahn School of Medicine at Mount Sinai chairs this session on cancer vaccines. Speakers include Parker Institute scientists Catherine Wu, M.D., of the Dana-Farber Cancer Institute and Robert Schreiber, Ph.D., of Washington University. Other speakers include Ugur Sahin, Ph.D., of BioNTech.
The Microbiome and Metabolism
Oct. 3, 2018, 10:45 a.m.-12:45 p.m. EDT
Jennifer Wargo, M.D., a Parker Institute scientist at The University of Texas MD Anderson Cancer Center, will present during this discussion on the intersection of cancer immunotherapy and the trillions of microbes that moderate the immune system. Laurence Zitvogel, M.D., Ph.D., of the Institut Gustave Roussy in France, is a chair of this panel.
Regulating T Cells and Their Response to Cancer
Sept. 30, 2018, 8:45-11:45 a.m. EDT
W. Nicholas Haining, B.M., B.Ch., a Parker Institute scientist at the Dana-Farber Cancer Institute, and Roberta Zappasodi, Ph.D., a Parker Scholar at Memorial Sloan Kettering Cancer Center, will present their research.
Please note that all events listed are subject to change. For the most up-to-date information, please view the event program online.
About the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy brings together the best scientists, clinicians and industry partners to build a smarter and more coordinated cancer immunotherapy research effort.
The Parker Institute is an unprecedented collaboration between the country’s leading immunologists and cancer centers. The program started by providing institutional support to six academic centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center. The institute also provides programmatic support for top immunotherapy investigators, including a group of researchers at Dana-Farber Cancer Institute, Robert Schreiber, PhD, of Washington University School of Medicine in St. Louis, Nina Bhardwaj, MD, PhD, of the Icahn School of Medicine at Mount Sinai, Philip Greenberg, MD, of the Fred Hutchinson Cancer Research Center, and Stephen Forman, MD, of City of Hope.
The Parker Institute network also includes more than 40 industry and nonprofit partners, more than 60 labs and more than 170 of the nation’s top researchers focused on treating the deadliest cancers. The goal is to accelerate the development of breakthrough immune therapies capable of turning most cancers into curable diseases. The institute was created through a $250 million grant from The Parker Foundation.
Parker Institute for Cancer Immunotherapy